Table 1 Patient characteristics
No. (%) of Patients | |
|---|---|
Age (yr) | |
Median | 80 |
Range | 75–87 |
Sex | |
Male | 19 (63.3) |
Female | 11 (36.7) |
Karnofsky performance status | |
100, 90 | 2 (6.7) |
80, 70 | 17 (56.7) |
60, 50 | 11 (36.7) |
Extent of resection | |
Total resection | 8 (26.7) |
Subtotal resection | 3 (10) |
Partial resection | 7 (23.3) |
Biopsy | 12 (40) |
Chemotherapy | |
Temozolomide | 20 (66.7) |
Temozolomide/Bevacizumab | 10 (33.3) |
Adjuvant Temozolomide cycles (n) | |
Median | 5 |
Range | 0–20 |
Use of corticosteroid | |
Yes | 6 (20) |
No | 24 (80) |
Treatment after tumor recurrence | |
Best supportive care | 21 (70) |
Bev | 5 (16.7) |
Surgery followed by Temozolomide | 1 (3.3) |
Temozolomide | 1 (3.3) |
No recurrence | 2 (6.7) |
MGMT promoter status | |
High | 11 (36.7) |
Low | 16 (53.3) |
N/A | 3 (10) |
IDH 1/2 status | |
Wild-type | 29 (96.7) |
Mutant | 0 |
N/A | 1 (3.3) |